

JPP

Journal of

Pharmacy and Pharmacology

**An international
journal of
pharmaceutical science**

Volume **56**

Number **12**

December 2004

ISSN 0022-3573

Targeting β -cell cyclic adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus

St. John's wort effects on brain serotonin transporter/uptake and behaviour in mice

Solid lipid nanoparticles (SLN) to improve oral bioavailability of poorly soluble drugs

PP
h
Pharmaceutical Press

Enhancement of natural killer cell activity of aged mice by modified arabinoxylan rice bran (MGN-3/Biobran)

Mamdooh Ghoneum and Sarah Abedi

Abstract

The present study is aimed to examine the possibility of enhancement of natural killer (NK) cell activity in aged C57BL/6 and C3H mice using MGN-3, a modified arabinoxylan from rice bran. Intraperitoneal injection of MGN-3 (10 mg kg⁻¹ per day) caused a remarkable increase in the peritoneal NK activity as early as 2 days (35.2 lytic units), and the level remained elevated through day 14. The control aged mice had a level of 5.8 lytic units. Enhancement in NK activity was associated with an increase in both the binding capacity of NK cells to tumour targets and in the granular content as measured by BLT-esterase activity. Treatment did not alter the percentage of peritoneal NK cells. Data showed that peritoneal macrophages inhibit NK activity. In conclusion, MGN-3 enhances murine NK activity of aged mice and may be useful for enhancing NK function in aged humans.

Introduction

Immunodeficiency of ageing is manifested in terms of increased infection, cancer and autoimmunity. Immunodeficiency is apparently a multifactorial problem, where the loss of immunologic vigour plays a major role in the above-mentioned diseases. For example, the number of white blood cell subpopulations does not change appreciably with age, however qualitative changes in the leukocytes do appear to occur with age (Itoh et al 1982; Albright & Albright 1983; Ghoneum et al 1991a, b; Miller 1996; Pawelec et al 1997, 1998; Greeley et al 2001; Rafi et al 2003). Several studies have shown that natural killer (NK) cells, the activity of which resides in large granular lymphocytes, are important in the natural resistance against tumour (Lotzova 1984; Moretta et al 2002), viral (Leong et al 1998; Biron et al 1999) and bacterial infection (Ghoneum et al 2003). The functional significance of these cells has attracted considerable interest for its possible role in host defence against cancer (Herberman 1983, 2002; Wu & Lanier 2003).

Our earlier studies (Ghoneum et al 1987, 1989, 1991a, b) and those of others (Itoh et al 1982; Albright & Albright 1983) clearly demonstrated an age-association defect in NK activity. Therefore, several attempts have been made to augment NK activity during ageing. Within the last two decades, extraordinary emphasis has been placed on biological response modifiers (BRMs) as anticancer agents: interleukin-2 (Konjevic et al 2003), interferon- γ (Appasamy et al 1994; Allavena et al 1998), killed streptococcal preparations (OK432) (Kurosawa et al 1996), *Corynebacterium parvum* (Ghoneum et al 1987), and bacilli Calmette-Guerin (Mizutani & Yoshida 1994). However, the clinical use of these BRMs has been severely limited because of their in-vivo cytotoxicity. In this study, we examined the effect of a food supplement, MGN-3, for possible enhancement of NK cell activity in aged mice. MGN-3 is an arabinoxylan from rice bran that has been modified by carbohydrate hydrolysing enzymes from shiitake mushrooms (Ghoneum 1998a). We have previously reported that MGN-3 enhances NK cell activity in healthy humans (Ghoneum 1998b), and increases the production of TNF- α by human peripheral blood lymphocytes (Ghoneum & Jewett 2000). It also sensitizes human leukaemia cells to death receptor (CD95) induced apoptosis (Ghoneum & Gollapudi 2003). In a double-blind study, Tazawa et al (2003) found a prophylactic effect with the use of MGN-3 against the common cold syndrome. In addition, MGN-3 accelerated the protection against severe loss of bodyweight of mice due to treatment with the chemotherapeutic agent cisplatin

Charles R. Drew University
of Medicine and Science,
Department of Otolaryngology,
Los Angeles, CA 90059, USA

Mamdooh Ghoneum,
Sarah Abedi

Correspondence: Mamdooh
Ghoneum, Charles R. Drew
University of Medicine and
Science, Department of
Otolaryngology, 1621 E. 120th
Street, Los Angeles, CA 90059,
USA. E-mail:
mghoneum@ucla.edu

Funding: This research was
supported by a grant from
Diawa Pharmaceutical Co. Ltd,
Tokyo, Japan and by NIH RCMI
grant G12RR03026.

(Jacoby et al 2001; Endo & Kambayashi 2003). In this study, we tested the ability of MGN-3 to enhance NK cell activity in aged mice, and to elucidate the possible mechanism that underlies the MGN-3 effect.

Materials and Methods

Animals and materials

The mice used in this study were the inbred strain of aged C57BL/6 and C3H female mice (18 months old) and were purchased from the Animal Laboratory, University of California, Berkeley, CA. Mice were housed five per cage and were permitted free access to water and food; they were accommodated for 1 week before experiments.

Complete medium (CM) consisted of RPMI-1640 supplemented with 10% fetal calf serum, 100 units penicillin and 100 μg streptomycin.

Target cells were the YAC-1 cell line, a Moloney leukaemia virus-induced mouse T-cell lymphoma of A/Sn mice origin, which was maintained in CM at a starting density of 3×10^5 cells mL^{-1} .

MGN-3 is an arabinoxylan extracted from rice bran that is treated enzymatically with an extract from shiitake mushrooms; it contains polysaccharides (β 1, 3-glucan and activated hemicellulose). MGN-3 was provided by Daiwa Pharmaceuticals Co., Ltd, Tokyo, Japan.

In-vivo treatment protocol

MGN-3 was orally administered to two groups of mice daily in a volume of 0.1 mL at a concentration of 10 mg mL^{-1} of MGN-3 (dry weight) in water or by intraperitoneal injection in a volume of 0.1 mL at the same concentration of MGN-3 in phosphate-buffered saline. The dose of 1 mg of MGN-3 per mouse was calculated from that recommended for humans (50 mg kg^{-1}). Control mice were given saline solution alone. At 2, 5 and 14 days after treatment, the peritoneal and splenic NK activity, as well as the cellularity of these tissues, were examined.

Preparation of peritoneal exudate cells (PECs), splenic NK cells and bone marrow NK cells

At 2, 5 and 14 days after treatment with MGN-3, mice were killed by cervical dislocation, and PECs were isolated as follows: 5 mL of HBSS was injected intraperitoneally, the abdomen was massaged and 90% of the injected volume was recovered. Cell viability was 95%, as determined by the trypan-blue exclusion test. Spleens were removed, teased in CM, and contaminating erythrocytes were lysed with distilled water. Splenic lymphocytes were pelleted, and washed three times with HBSS. Bone marrow cells were flushed out from femur and tibia and washed in HBSS.

Measuring NK activity by the ^{51}Cr -released assay

The ^{51}Cr -released assay was used to determine NK cell activity in the peritoneum, spleen and bone marrow.

In brief, 5×10^6 YAC-1 cells were labelled with $100 \mu\text{Ci } ^{51}\text{CrO}_4$ solution (New England Nuclear, Boston, MA) for 1 h at 27°C . Cells were washed four times with HBSS and resuspended in CM at 1×10^5 cells mL^{-1} . YAC-1 cells (1×10^4) were then pipetted into each well of 96-well round-bottomed Linbro plates. Effector cells were pipetted to quadruplicate wells to give effector/target cells ratios of 25:1, 50:1 and 100:1. The plates were incubated at 37°C for 4 h, then centrifuged at $1000g$ for 5 min, and 0.1 mL of supernatant from each well was collected and counted in a gamma counter. The percentage of isotope released was calculated by the following formula:

$$\text{Lysis (\%)} = \frac{(\text{experimental release} - \text{spontaneous release})}{(\text{total release} - \text{spontaneous release})} \times 100$$

where spontaneous release is cpm from YAC-1 incubated in CM without effector cells and total release is cpm from YAC-1 incubated in Triton X-100. Results were expressed in lytic units (LU)/ 10^7 , with 1 LU being the number of effector cells required to lyse 5% and 15% of YAC-1 targets by peritoneal NK (P-NK) and splenic NK cells, respectively.

Flow cytometry

PECs were prepared from saline-treated and MGN-3-treated mice. The percentage of peritoneal NK (P-NK) cells was demonstrated by their expression of NK1.1 marker, and determined by flow cytometry. Cells were first gated with forward and side scatter characteristics, and then the percentage of surface marker positive cells was measured. The monoclonal antibodies used were anti-NK1.1 (Pharmingen, San Diego, CA).

BLT-esterase release assay

N-a-CBZ-L-lysine thiobenzyl ester (BLT)-esterase activity was examined according to the procedure of Green & Shaw (1979) with little modification. In brief, PECs (3×10^6 cells mL^{-1} , $100 \mu\text{L}/\text{well}$), from MGN-3- and saline-treated aged mice were incubated with YAC-1 target cells (9×10^6 cells mL^{-1} , $100 \mu\text{L}/\text{well}$) for 4 h at 37°C in RPMI 1640, in V-bottomed 96-microwell plates. The relative amount of secreted BLT-esterase activity was determined by incubating triplicate samples of supernatant ($100 \mu\text{L}$) and reaction buffer ($100 \mu\text{L}$) for 30 min at 37°C in 96-well ELISA plates. The reaction buffer contained 0.1 M Tris-HCl, pH 8.1, 0.2 mM DTNB, and 0.2 mM BLT (Sigma, St Louis, MO). The colour was allowed to develop for 40 min. Optical density readings were taken at 405 nm using an ELISA plate reader.

Morphological assessment of NK granularity

The effect of MGN-3 on the level of granularity of P-NK cells was examined in cytopsin preparations as previously described (Itoh et al 1982). P-NK cells were purified as follows: macrophages and B-cells were removed by sequential incubation in CM in 150- cm^2 flasks for 1 h at 37°C and on nylon wool columns. Non-adherent mononuclear cells from nylon wool columns were fractionated by overlaying onto Percoll discontinuous gradients. For morphological

assessment of NK granularity, P-NK cells (10^5 mL^{-1}) from MGN-3- and saline-treated aged mice were centrifuged on slides at 200g for 5 min using a cytospin cytocentrifuge (Shandon Southern Inst., Sewickley, PA, USA). Slides were air dried, fixed in 100% MeOH for 5 min, and then stained with 4% Giemsa solution for 15 min.

Percentage conjugate formation

The percentage of conjugate formation between P-NK cells and YAC-1 cells was examined in cytospin preparations (Itoh et al 1982). In brief, peritoneal non-adherent cells (10^5 mL^{-1}) from MGN-3- and saline-treated aged mice were mixed with YAC-1 cells ($10^6 \text{ cells mL}^{-1}$) at 4°C for 1 h. The cells were centrifuged on slides at 200g for 5 min using a cytospin cytocentrifuge and stained with Giemsa as previously described. The percentage of NK cells binding to YAC-1 cells within 200 cells was calculated in triplicate samples.

Suppressive effect of peritoneal macrophage (P-MØ) on P-NK cell activity

A set of experiments was carried out to examine the suppressive effect of P-MØ on P-NK cell activity. C57BL/6 mice were injected intraperitoneally with MGN-3 for 5 days and the natural cytotoxicity by P-MØ, PECs, and PECs depleted of P-MØ (non-adherent cells) was examined separately by ^{51}Cr -released assay.

Admixture of P-MØ added to the non-adherent cells

To further confirm the suppressive effect of P-MØ, an admixture of equal numbers of P-MØ and non-adherent cells was examined for NK activity. The admixture contained cells at an effector/target ratio of 50:1. Results were compared with non-adherent cells alone.

MGN-3 treatment by oesophageal tubing

Another set of experiments was carried out to examine splenic NK activity in C57BL/6 mice. The mice were given

MGN-3 through oesophageal tubing at a concentration of 10 mg in 100 μL distilled water/mouse. After 14 days, the mice were killed and examined for splenic NK activity.

In-vitro effect of MGN-3 on NK activity

Splenic cells ($1 \times 10^6 \text{ cells mL}^{-1}$) from aged C57BL/6 mice were cultured with MGN-3 at concentrations of 25 and 100 $\mu\text{g mL}^{-1}$. At 16 h after treatment, cells were washed twice in CM and were examined for NK activity.

Statistical analysis

A two-tailed Student's *t*-test was used to determine the degree of significance between NK cell activity of control and MGN-3-treated mice.

Results

Peritoneal and splenic cellularity

Results of the effect of intraperitoneal treatment with MGN-3 on peritoneal and splenic cellularity are shown in Table 1. MGN-3 significantly increased peritoneal cellularity (404–470% of control) in C57BL/6 and C3H mice. The effect was noted as early as 2 days, and remained elevated through day 14. An increase in splenic cellularity in both strains of mice was also noted but to a lesser extent (145–192% of control).

NK activity after intraperitoneal injection

Results in Table 2 show that intraperitoneal injection with MGN-3 resulted in enhancement in P-NK activity. This was detected as early as 2 days (35.2 LU), and the level remained elevated through Day 14 as compared with saline-treated aged mice. A similar pattern of increase was observed with the P-NK activity of C3H mice after injection with MGN-3. However, intraperitoneal treatment with MGN-3 did not increase splenic NK cell activity at 2, 5 or 14 days after treatment in either strain of mice (Table 2).

Table 1 In-vivo effect of MGN-3 on tissue cellularity

Strain of mice	Time after MGN-3 treatment (days)	Splenic cells ($\times 10^6$)		Peritoneal cells ($\times 10^6$)	
		MGN-3	Control	MGN-3	Control
C57BL/6	2	$60 \pm 1^{**}$ (150%)	40 ± 2.3	$9.4 \pm 1^*$ (470%)	2.0 ± 0.08
	5	$61 \pm 0.08^{**}$ (145.2%)	42 ± 0.08	9.7 ± 0.08 (461.9%)	2.1 ± 0.08
	14	$85.5 \pm 1.75^{**}$ (192%)	44.5 ± 2.1	$8.5 \pm 1.05^*$ (404.7%)	2.1 ± 0.5
C3H	5	$70 \pm 2.5^{**}$ (166.7%)	42 ± 3.7	$6.8 \pm 0.4^*$ (453.3%)	1.5 ± 0.3

The percentage induction is given in parentheses. Data represent the mean percentage of total peritoneal and splenic cells from C57BL/6 and C3H mice after intraperitoneal treatment with MGN-3. Means \pm s.e.m of six mice at each time point were examined separately. * $P < 0.01$, ** $P < 0.025$, significantly different compared with control saline-treated aged mice.

Table 2 Effect of intraperitoneal injection of MGN-3 on natural killer (NK) cell activity in the peritoneal cavity (PC) and spleen

Strain of mice	Treatment	Day of assay	NK activity							
			PC				Spleen			
			25:1	50:1	100:1	LU 5%	25:1	50:1	100:1	LU 15%
C57BL/6	Saline	2	1.1	1.5	2.5	5.8	4.1	9.3	14.3	9.6
	MGN-3	2	4.0	7.1	9.2	35.2*	2.5	8.2	11.9	9.0
	Saline	5	0.8	1.7	2.4	6.2	5.1	8.0	10.3	7.7
	MGN-3	5	3.9	8.1	11.2	37.0*	6.1	9.2	14.0	9.2
	Saline	14	1.3	2.2	3.0	6.6	5.3	8.3	14.4	9.1
	MGN-3	14	4.4	6.7	8.8	34.0*	5.5	7.8	12.5	8.5
C3H	Saline	5	0.1	0.3	1.0	5.0	3.8	8.4	13.0	9.1
	MGN-3	5	1.2	2.4	7.5	24.1*	4.5	10.5	14.5	10.0

MGN-3 was injected into C57BL/6 and C3H mice. Pooled lymphoid cells were prepared from the peritoneal cavity or spleens of saline- or MGN-3-treated mice. Cells were harvested at 2, 5 and 14 days after treatment. NK activity was assayed in a 4-h Cr-release assay against YAC-1 target cells at effector/target cell ratios of 25:1, 50:1 and 100:1 and expressed as the number of lytic units (LU). * $P < 0.01$, significantly different compared with saline-treated mice.

Bone marrow NK activity

Bone marrow NK activity was examined in C57BL/6 mice at 14 days after intraperitoneal injection with MGN-3. As shown in Figure 1, MGN-3 did not significantly increase either NK cell activity or the number of cells as compared with control mice.

NK activity after oral treatment

Oesophageal tubing of 10 mg in 100 μ L/mouse resulted in a 200% increase in splenic NK cell activity in C57BL/6 mice at 14 days after treatment. On the other hand, P-NK cells showed no change in activity after treatment with MGN-3 as compared with saline-treated mice (Table 3).

Percentage of P-NK cells

A surface marker for NK cells, NK1.1, was used to examine the frequency of P-NK cells. Results showed no significant differences in the percentages of P-NK cells between the mice treated with MGN-3 (16%) and those treated with saline (14%).

Percentage conjugate formation

The effect of MGN-3 on the binding capacity of P-NK cells to YAC-1 cells was examined in cytospin preparations. As shown in Figure 2, MGN-3-treated P-NK cells demonstrated 26% conjugate formation as compared with saline-treated P-NK cells (13%); this represents a 2-fold increase.

Granularity of P-NK cells

MGN-3-treated P-NK cells demonstrated a remarkable increase in the BLT-esterase activity. Figure 3 shows an

increase in the BLT-esterase activity at 5 days as compared with saline-treated mice. This observation was further confirmed in cytospin preparations. Figure 3B,C shows NK cells from aged mice with a low or absent granular




Figure 1 In-vivo action of MGN-3 on bone marrow natural killer (NK) cell activity. A. NK activity in C57BL/6 mice was examined 14 days after intraperitoneal treatment with MGN-3. Activity of NK cells was measured by 4-h Cr-release assay at an effector/target ratio of 100:1. B. The cell number of bone marrow was also examined. Data are mean \pm s.e.m of four mice examined separately.

Table 3 Effect of oral treatment of MGN-3 on natural killer (NK) cell activity in the peritoneal (PC) cavity and spleen

Treatment	Day of assay	NK activity							
		PC				Spleen			
		25:1	50:1	100:1	LU 5%	25:1	50:1	100:1	LU 15%
Saline	14	0.3	1.1	2.0	5.5	4.1	8.0	10.6	8.4
MGN-3	14	0.6	2.1	3.3	6.3	8.1	16.2	19.9	16.7*

MGN-3 was injected into C57BL/6 mice. Pooled lymphoid cells were prepared from the peritoneal cavity or spleens of saline- or MGN-3-treated mice. Cells were harvested 14 days after treatment. NK activity was assayed in a 4-h Cr-release assay against YAC-1 target cells at effector/target cell ratios of 25:1, 50:1 and 100:1 and expressed as number of lytic units (LU). * $P < 0.01$, significantly different compared with saline-treated mice.




Figure 2 Percentage conjugates between natural killer (NK) cells and YAC-1 target cells from C57BL/6 mice examined at 5 days after intraperitoneal injection with MGN-3 and saline. * $P < 0.01$, compared with control saline-treated mice.

content, yet MGN-3-treated mice at 5 days demonstrated an increase in NK cell granular content.

Suppressive effect of P-MØ on P-NK cell activity

The suppressive effect of P-MØ on P-NK cell activity after treatment with MGN-3 was examined. Figure 4A shows that P-MØ alone showed an undetectable level of anti-tumour activity. On the other hand, natural cytotoxicity by MGN-3-treated PEC showed 7%, while PEC depleted of P-MØ (the non-adherent cells) demonstrated a further increase to 16%. An admixture of P-MØ and non-adherent cells resulted in a significant inhibition of NK activity exhibited by non-adherent cells (33%) as compared with non-adherent cells alone (Figure 4B).

In-vitro action of MGN-3 on NK activity

Culture of lymphocytes from aged C57BL/6 mice with MGN-3 for 16 h resulted in a significant induction of NK activity as follows: 21 and 23 LU at a concentration of 25 and 100 $\mu\text{g mL}^{-1}$, respectively, as compared with control untreated cells (Figure 5).




Figure 3 A. In-vivo action of MGN-3 on BLT-esterase activity. BLT-esterase activity was examined in C57BL/6 mice injected intraperitoneally with MGN-3 and saline. Data are mean \pm s.e.m. of three experiments. * $P < 0.01$, significantly different compared with control saline-treated aged mice. B. Cytocentrifuge preparation of peritoneal NK (P-NK) cells of saline-treated mice. P-NK cells were used in a purified form using Percoll discontinuous gradients. Notice the high nuclear cytoplasmic ratio and absence of granules in control aged mice. C. Preparation of NK cells after MGN-3 treatment. Notice the high granularity of NK cells. Notice one NK cell with an arrow pointing to the granules. (Giemsa stain, $\times 740$.)




Figure 4 In-vivo effect of MGN-3 on peritoneal exudate cells (PECs), macrophages (P-MØ), and non-adherent cells. A. Aged C57BL/6 mice were injected intraperitoneally with MGN-3 for 5 days and natural killer (NK) activity was examined at an effector/target ratio of 50:1 (A). * $P < 0.025$, compared with PECs. B. Admixture of P-MØ to non-adherent cells from MGN-3-treated aged mice. NK activity was examined at an effector/target ratio of 50:1. * $P < 0.025$, significantly different compared with non-adherent cells alone.




Figure 5 In-vitro action of MGN-3 on natural killer (NK) cell activity. Splenic lymphocytes from aged C57BL/6 mice were cultured for 16 h in the presence or absence of MGN-3. Activity was measured by 4-h Cr-release assay and expressed as number of lytic units (LU). Data are mean \pm s.e.m of three experiments. * $P < 0.01$, significantly different compared with control untreated cells.

Discussion

In the present study, we demonstrated that MGN-3 enhances murine NK activity in aged mice both in-vivo and in-vitro. The increase in NK activity was not due to

simple intercompartmental redistribution of NK cells, but rather to an actual increase in the activity of the effector cells. This was evidenced by examining the NK activity and the cell number of other lymphoid organs. Intraperitoneal injection with MGN-3 did not significantly alter NK activity in the spleen or bone marrow, despite an increase in cellularity.

The mechanism by which MGN-3 enhances murine NK activity may involve enhancing both the binding and the lethal hit. The study showed an increase in the percentage of conjugates of NK cells to their tumour targets after treatment with MGN-3, which may be attributed to an increase in the expression of adhesion molecule (ICAM-1) on NK cells (Ghoneum & Jewett 2000) or other cell surface markers, for example LFA-1. The increase in conjugation after treatment with MGN-3 may also suggest involvement of other effector cytotoxic cells such as CTL killing YAC-1 targets, since the percentage of NK cells did not alter with MGN-3. The study also indicated an increase in the activity of the granule lytic BLT-esterase. It has been reported that aging is associated with a decline in the percentage of murine NK cells that carry granules (Ghoneum et al 1989), and in the perforin expression in aged human NK cells (Rukavina et al 1998).

Data demonstrated that P-MØ exhibit an inhibitory effect on NK cells. This was indicated by the ability of MGN-3 to significantly increase the activity of P-NK cells that had been depleted of MØ. Earlier studies by Irimajiri et al (1985) suggested that the active adherent suppressor cells, possibly macrophages, are responsible for the suppression of aged murine NK cell activity. We do not know the mechanism by which P-MØ suppress P-NK activity after treatment with MGN-3, but it may involve increased production of H_2O_2 (Kono et al 1996).

The increase in P-NK activity and in PECs is due to the direct effect of MGN-3; the possibility that repeated injections of MGN-3 caused any persistent peritoneal inflammation was excluded since control mice were repeatedly subjected to injections of saline solutions without the increase in P-NK activity or in PECs. The immunomodulatory effect of MGN-3 was further confirmed by in-vitro studies of a co-culture of MGN-3 with NK cells for 16 h. The increase in both splenic and peritoneal cellularity was a consistent finding in both strains of mice. The reason for this finding is not clear but it could be attributed to cell proliferation in these compartments. We have previously reported a significant increase in human T- and B-cell proliferation after ingestion of MGN-3 (Ghoneum 1998a). Further studies are needed to clarify this point.

The inability of MGN-3 to enhance splenic NK activity in-vivo is not fully understood, but it could be attributed to the dilution of NK cells in the spleen due to an expansion of other cell populations. As shown in Table 1, splenic cellularity in MGN-3-treated mice was increased. It has been reported that NK cells in different tissues display a differential response towards the enhancing effect of other BRMs. For example, treatment with *Candida albicans* remarkably increased P-NK activity without an effect on splenic NK activity (Marconi et al 1985). On the other

hand, introducing MGN-3 into the mice by oesophageal tubing increased splenic NK activity (200% as compared with control mice). This suggests that the enhancement of splenic NK cell activity depends on how this agent is introduced into the body.

Conclusions

The results of the present study show that intraperitoneal injection and oral treatment with MGN-3 resulted in a significant enhancement of murine peritoneal and splenic NK cell activity, respectively. The increase in NK activity was associated with an increased level of NK granularity. We conclude that MGN-3 has the ability to enhance NK activity in aged mice and may be useful for enhancing the NK function in ageing humans.

References

- Albright, J. W., Albright, J. F. (1983) Age-associated impairment of murine natural killer activity. *Proc. Natl Acad. Sci. USA* **80**: 6371–6375
- Allavena, P., Giardino, G., Sen, S., Colella, G., Brogini, M., D'Incalci, M. (1998) IFN-beta partially counteracts inhibition of natural killer activity induced by some antitumor agents. *J. Interferon Cytokine Res.* **18**: 87–93
- Appasamy, R., Bryant, J., Hassanein, T., Van Thiel, D. H., Whiteside, T. L. (1994) Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C. *Clin. Immunol. Immunopathol.* **73**: 350–357
- Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., Salazar-Mather, T. P. (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. *Annu. Rev. Immunol.* **17**: 189–220
- Endo, Y., Kambayashi, H. (2003) Modified rice bran beneficial of weight loss of mice as a major and acute adverse effect of cisplatin. *Pharmacol. Toxicol.* **92**: 300–303
- Ghoneum, M. (1998a) Anti-HIV activity in vitro of MGN-3, an activated arabinoxylan from rice bran. *Biochem. Biophys. Res. Commun.* **243**: 25–29
- Ghoneum, M. (1998b) Enhancement of human natural killer cell activity by modified arabinoxylan from rice bran (MGN-3). *Int. J. Immunother.* **14**: 89–99
- Ghoneum, M., Jewett, A. (2000) Production of tumor necrosis factor- α and interferon- γ from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro. *Cancer Detect. Prev.* **24**: 314–324
- Ghoneum, M., Gollapudi, S. (2003) Modified arabinoxylan rice bran (MGN-3/Biobran) sensitizes human T cell leukemia cells to death receptor (CD95)-induced apoptosis. *Cancer Lett.* **20**: 41–49
- Ghoneum, M., Gill, G., Wojdani, A., Payne, C., Alfred, L. J. (1987) Suppression of basal and *Corynebacterium parvum*-augmented NK activity during chemically induced tumor development. *Int. J. Immunopharmacol.* **9**: 71–78
- Ghoneum, M., Salem, F., Gill, G., Jackson, K., Betru, Y., Allen, H. (1989) NK cell activity and tumor development of age-related variation to 3-methylcholanthrene. In: Ades, E. W., Lopes, C. (eds) *Natural killer cells and host defense*. Karger, Basel, pp 278–284
- Ghoneum, M., Jackson, K., Salem, F., Gill G. (1991a) Murine inter-sex difference in methylcholanthrene induced tumor and its correlation with NK activity. *Int. J. Immunopathol. Pharmacol.* **4**: 9–18
- Ghoneum, M., Suzuki, K., Gollapudi, S. (1991b) Phorbol myristate acetate corrects impaired NK function of old mice. *Scand. J. Immunol.* **34**: 391–398
- Ghoneum, M., Saglie, R., Brown, J., Regala, C. (2003) *Actinobacillus actinomycetemcomitans* suppresses rat natural killer cell activity in vivo. *Acta. Otolaryngologica* **123**: 1–7
- Greeley, E. H., Ballam, J. M., Harrison, J. M., Kealy, R. D., Lawler, D. F., Segre, M. (2001) The influence of age and gender on the immune system: a longitudinal study in Labrador retriever dogs. *Vet. Immunol. Immunopathol.* **82**: 57–71
- Green, G. D., Shaw, E. (1979) Thiobenzyl benzyloxycarbonyl-L-lysinate, substrate for a sensitive colorimetric assay for trypsin-like enzymes. *Anal. Biochem.* **93**: 223–226
- Herberman, R. B. (1983) Possible role of natural killer cells in host resistance against tumors and other diseases. *Clin. Immunol. Allergy* **3**: 479–485
- Herberman, R. B. (2002) Cancer immunotherapy with natural killer cells. *Semin. Oncol.* **29**: 27–30
- Irimajiri, N., Bloom, E. T., Makinodan, T. (1985) Suppression of murine natural killer cell activity by adherent cells from aging mice. *Mech. Ageing Dev.* **31**: 155–162
- Itoh, K., Suzuki, R., Umezu, Y., Hanaumi, K., Kumagai, K. (1982) Studies of murine large granular lymphocytes. II Tissue, strain and age distribution of LGL and LAL. *J. Immunol.* **129**: 395–405
- Jacoby, H. I., Wnorowski, G., Sakata, K., Maeda, H. (2001) The effect of MGN-3 on cisplatin and doxorubicin induced toxicity in the rat. *J. Nutraceuticals Funct. Med. Foods* **3**: 3–11
- Konjevic, G., Jovic, V., Jurisic, V., Radulovic, S., Jelic, S., Spuzic, I. (2003) IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. *Clin. Exp. Metastasis* **20**: 647–655
- Kono, K., Salazar-Onfray, F., Petersson, M., Hansson, J., Masucci, G., Wasserman, K., Nakazawa, T., Anderson, P., Kiessling, R. (1996) Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. *Eur. J. Immunol.* **26**: 1308–1313
- Kurosawa, S., Harada, M., Shinomiya, Y., Terao, H., Nomoto, K. (1996) The concurrent administration of OK432 augments the antitumor vaccination effect with tumor cells by sustaining locally infiltrating natural killer cells. *Cancer Immunol. Immunother.* **43**: 31–38
- Leong, C. C., Chapman, T. L., Bjorkman, P. J., Formankova, D., Mocarski, E. S., Phillips, J. H., Lanier, L. L. (1998) Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. *J. Exp. Med.* **187**: 1681–1687
- Lotzova, E. (1984) The role of natural killer cells in immune surveillance against malignancies. *Cancer Bull.* **36**: 215
- Marconi, P., Scaringi, L., Tissi, L., Boccanera, M., Bistoni, F., Bonmassar, E., Cassone, A. (1985) Induction of natural killer cell activity by inactivated *Candida albicans* in mice. *Infect. Immunol.* **50**: 297–303
- Miller, R. A. (1996) The aging immune system: primer and prospectus. *Science* **273**: 70–74
- Mizutani, Y., Yoshida, O. (1994) In vitro enhancement of natural killer cell activity by BCG and the antagonistic inhibition of the susceptibility of K562 cells to lysis by peripheral blood

- lymphocytes in patients with urinary bladder tumor. *Int. J. Urol.* **1**: 49–56
- Moretta, L., Bottino, C., Pende, D., Mingari, M. C., Biassoni, R., Moretta, A. (2002) Human natural killer cells: their origin, receptors and function. *Eur. J. Immunol.* **32**: 1205–1211
- Pawelec, G., Adibzadeh, M., Solana, R., Beckman, I. (1997) The T cell in the ageing individual. *Mech. Ageing Dev.* **93**: 35–45
- Pawelec, G., Solana, R., Remarque, E., Mariani, E. (1998) Impact of aging on innate immunity. *J. Leukoc. Biol.* **64**: 703–712
- Rafi, A., Castle, S. C., Uyemura, K., Makinodan, T. (2003) Immune dysfunction in the elderly and its reversal by antihistamines. *Biomed. Pharmacother.* **57**: 246–250
- Rukavina, D., Laskarin, G., Rubesa, G., Strbo, N., Bedenicki, I., Manestar, D., Glavas, M., Christmas, S. E., Podack, E. R. (1998) Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells. *Blood* **92**: 2410–2420
- Tazawa, K., Ichihashi, K., Fujii, T., Omura, K., Anazawa, M., Maeda, H. (2003) The orally administration of the hydrolysis rice bran prevents a common cold syndrome for the elderly people based on immunomodulatory function. *J. Trad. Med.* **20**: 132–141
- Wu, J., Lanier, L. L. (2003) Natural killer cells and cancer. *Adv. Cancer Res.* **90**: 127–56